Eli Lilly and Novo Nordisk reported second-quarter results this week that highlighted a growing divergence in investor sentiment toward the two obesity and diabetes drug manufacturers. Both companies exceeded analyst expectations and raised their full-year revenue guidance, yet the market’s reaction differed sharply. Lilly’s stock rose following its announcement, while Novo experienced a sell-off, reflecting deepening concerns about the Danish company’s long-term growth prospects.
Lilly demonstrated continued momentum with revenue growth of 48% year-over-year, driven by strong demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company expanded its market share in the United States to 60.9% in the obesity and diabetes drug category during the second quarter, compared with Novo’s 38.8%. Lilly’s raised guidance reinforced investor confidence that its portfolio can sustain sales growth even as prices face downward pressure in the U.S. market.
Novo’s results presented a more complicated picture. While the company exceeded sales expectations and benefited from rebate adjustments, its oral obesity treatment Wegovy pill came in slightly below analyst forecasts. The pill has reached over 5 million patients since launching in the U.S. in January and launched in Germany during September. However, the shortfall raised questions about whether the product can become a sufficiently large growth driver. Additionally, trial results for CagriSema, an experimental obesity drug, showed it could not match Zepbound’s efficacy in controlling blood sugar levels—the second such failure this year.
Pipeline concerns intensified when Novo disclosed that ziltivekimab, a late-stage experimental heart drug, failed to reduce cardiovascular events compared to placebo. That setback diminished investor hopes for portfolio diversification beyond obesity and diabetes treatments. Analysts emphasized that as pricing pressures persist in the obesity market, Novo must demonstrate clearer strategic direction and expanded therapeutic offerings to regain market confidence.
The contrast between the two companies has become pronounced: Lilly is viewed as the market leader with sustained momentum, while Novo remains in what analysts call a “show-me phase,” awaiting evidence that its turnaround strategy will succeed. Wall Street’s assessment reflects concerns that Novo’s current portfolio may face sustainability challenges without successful pipeline advancement.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI